Kenneth Haire has been named as a new director at Millstone Medical Outsourcing, LLC. Haire, who will lead the team as Director of Quality Systems in Olive Branch, Mississippi, brings 22 years of experience to his new post. He will be responsible for developing, coordinating, and maintaining company-wide compliance systems and working closely with customers to ensure the highest quality standards possible.
Kenneth Haire New Director at Millstone Medical

Most recently, Haire served as Upstream Quality Manager where he led his quality team in design transfer and new product solutions. Haire started his career as a Quality Tech back in 1991 after which he experienced consistent internal growth holding integral roles in the following positions: Quality Supervisor, Quality Engineer, Validation Engineer and Senior Upstream Quality Engineer.
“Millstone’s entire business model is built around our robust quality system, ” said Chris Ramsden, Millstone chief executive officer, in the October 2, 2013 news release. “Kenneth has dedicated his entire career to enhancing the quality system of one of the world’s top medical device companies. We have great confidence that he will ensure the continuation of our quality assurance and will enhance our systems as we continue to experience rapid growth. We are excited to welcome Kenneth to our team.”
Mr. Haire told OTW, “My first step as Director of Quality will be to gain a comprehensive understanding of Millstone’s quality protocols and procedures. I look forward to integrating my expertise with Millstone’s quality team and enhancing their systems as they continue to grow.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.